Trial Profile
VELCADE (Bortezomib) for Injection - Phase II Study of Bortezomib and Rituximab in Relapsed or Refractory Non-Hodgkin's Lymphoma
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Rituximab (Primary)
- Indications Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- 25 Jan 2008 Status changed from recruiting to discontinued. According to ClinicalTrials.gov, the study was withdrawn due to poor accrual.
- 19 Aug 2006 New trial record.